XML 126 R63.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Disaggregation of Revenue |  |  |  |
Total net revenues | $ 15,776 | $ 14,460 | $ 44,542 | $ 41,232
All other |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 660 | 726 | 2,010 | 2,280
Immunology | Skyrizi |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 4,708 | 3,205 | 12,556 | 7,940
Immunology | Skyrizi | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 4,085 | 2,778 | 10,847 | 6,774
Immunology | Skyrizi | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 623 | 427 | 1,709 | 1,166
Immunology | Rinvoq |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 2,184 | 1,614 | 5,930 | 4,137
Immunology | Rinvoq | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 1,559 | 1,170 | 4,231 | 2,912
Immunology | Rinvoq | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 625 | 444 | 1,699 | 1,225
Immunology | Humira |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 993 | 2,227 | 3,294 | 7,311
Immunology | Humira | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 619 | 1,765 | 2,165 | 5,896
Immunology | Humira | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 374 | 462 | 1,129 | 1,415
Neuroscience | Vraylar |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 934 | 875 | 2,599 | 2,343
Neuroscience | Vraylar | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 931 | 873 | 2,592 | 2,338
Neuroscience | Vraylar | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 3 | 2 | 7 | 5
Neuroscience | Botox Therapeutic |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 985 | 848 | 2,779 | 2,410
Neuroscience | Botox Therapeutic | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 825 | 708 | 2,323 | 1,988
Neuroscience | Botox Therapeutic | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 160 | 140 | 456 | 422
Neuroscience | Ubrelvy |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 354 | 269 | 932 | 703
Neuroscience | Ubrelvy | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 344 | 261 | 907 | 685
Neuroscience | Ubrelvy | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 10 | 8 | 25 | 18
Neuroscience | Qulipta |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 288 | 176 | 748 | 457
Neuroscience | Qulipta | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 252 | 168 | 661 | 442
Neuroscience | Qulipta | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 36 | 8 | 87 | 15
Neuroscience | Vyalev |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 138 | 28 | 299 | 55
Neuroscience | Vyalev | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 53 | 0 | 81 | 0
Neuroscience | Vyalev | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 85 | 28 | 218 | 55
Neuroscience | Duodopa |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 96 | 111 | 289 | 339
Neuroscience | Duodopa | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 16 | 24 | 56 | 72
Neuroscience | Duodopa | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 80 | 87 | 233 | 267
Neuroscience | Other Neuroscience |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 46 | 56 | 160 | 183
Neuroscience | Other Neuroscience | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 42 | 54 | 148 | 172
Neuroscience | Other Neuroscience | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 4 | 2 | 12 | 11
Oncology | Imbruvica |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 706 | 828 | 2,198 | 2,499
Oncology | Imbruvica | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 507 | 618 | 1,579 | 1,823
Oncology | Imbruvica | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Collaboration revenues | $ 199 | $ 210 | $ 619 | $ 676
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] | Total net revenues | Total net revenues | Total net revenues | Total net revenues
Oncology | Venclexta |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | $ 726 | $ 677 | $ 2,082 | $ 1,928
Oncology | Venclexta | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 341 | 340 | 974 | 921
Oncology | Venclexta | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 385 | 337 | 1,108 | 1,007
Oncology | Elahere |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 170 | 139 | 508 | 331
Oncology | Elahere | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 150 | 139 | 453 | 331
Oncology | Elahere | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 20 | 0 | 55 | 0
Oncology | Epkinly |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 69 | 43 | 190 | 106
Oncology | Epkinly | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Collaboration revenues | $ 44 | $ 31 | $ 129 | $ 82
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] | Total net revenues | Total net revenues | Total net revenues | Total net revenues
Oncology | Epkinly | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | $ 25 | $ 12 | $ 61 | $ 24
Oncology | Other Oncology | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 11 | 0 | 13 | 0
Aesthetics | Botox Cosmetic |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 637 | 671 | 1,885 | 2,033
Aesthetics | Botox Cosmetic | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 379 | 414 | 1,084 | 1,253
Aesthetics | Botox Cosmetic | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 258 | 257 | 801 | 780
Aesthetics | Juvederm Collection |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 253 | 258 | 744 | 898
Aesthetics | Juvederm Collection | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 98 | 105 | 278 | 349
Aesthetics | Juvederm Collection | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 155 | 153 | 466 | 549
Aesthetics | Other Aesthetics |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 303 | 310 | 945 | 947
Aesthetics | Other Aesthetics | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 265 | 272 | 817 | 828
Aesthetics | Other Aesthetics | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 38 | 38 | 128 | 119
Eye Care | Ozurdex |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 117 | 119 | 365 | 374
Eye Care | Ozurdex | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 32 | 33 | 92 | 102
Eye Care | Ozurdex | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 85 | 86 | 273 | 272
Eye Care | Lumigan/Ganfort |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 97 | 116 | 306 | 310
Eye Care | Lumigan/Ganfort | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 42 | 58 | 142 | 129
Eye Care | Lumigan/Ganfort | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 55 | 58 | 164 | 181
Eye Care | Alphagan/Combigan |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 47 | 62 | 143 | 170
Eye Care | Alphagan/Combigan | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 9 | 26 | 35 | 54
Eye Care | Alphagan/Combigan | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 38 | 36 | 108 | 116
Eye Care | Other Eye Care |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 248 | 228 | 715 | 742
Eye Care | Other Eye Care | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 138 | 123 | 399 | 421
Eye Care | Other Eye Care | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 110 | 105 | 316 | 321
Other Key Products | Mavyret |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 312 | 302 | 993 | 1,020
Other Key Products | Mavyret | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 146 | 147 | 472 | 458
Other Key Products | Mavyret | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 166 | 155 | 521 | 562
Other Key Products | Creon | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 368 | 338 | 1,127 | 995
Other Key Products | Linzess/Constella |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 326 | 234 | 732 | 721
Other Key Products | Linzess/Constella | United States |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | 315 | 225 | 701 | 693
Other Key Products | Linzess/Constella | International |  |  |  |
Disaggregation of Revenue |  |  |  |
Net revenues | $ 11 | $ 9 | $ 31 | $ 28

X
- Definition Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abbv_KeyProductPortfolioAxis=abbv_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_SKYRIZIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_RINVOQMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_HUMIRAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abbv_KeyProductPortfolioAxis=abbv_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_VraylarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_BotoxTherapeuticMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_UbrelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_QuliptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_VyalevMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_DuodopaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_OtherNeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abbv_KeyProductPortfolioAxis=abbv_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_ImbruvicaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_VENCLEXTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_ElahereMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_EpkinlyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abbv_KeyProductPortfolioAxis=abbv_AestheticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_BotoxCosmeticMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_JuvedermCollectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_OtherAestheticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abbv_KeyProductPortfolioAxis=abbv_EyeCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_OzurdexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_LumiganGanfortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_AlphaganCombiganMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_OtherEyeCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abbv_KeyProductPortfolioAxis=abbv_OtherKeyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_MAVYRETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_CreonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=abbv_LinzessConstellaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |